Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche's GLP-1 taspoglutide posts good results for A1c control, weight loss, but safety concerns persist

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Once-weekly taspoglutide, Roche's bid to diversify into the diabetes market, controlled blood glucose as well as or better than more frequent treatments with Sanofi-Aventis' Lantus (insulin glargine), Lilly/Amylin/Alkermes' Byetta (twice-daily exenatide) or Merck's Januvia (sitagliptin) in Phase III studies reported at the American Diabetes Association scientific sessions in Orlando, Fla., June 26 (1Health News Daily, June 29, 2010). Compared to Januvia and Lantus, taspoglutide patients also lost significantly more weight, while the performance on that measure was about the same as with Byetta. Safety data from those same trials, however, gave new weight to the announcement earlier in the month that Roche has instituted a risk management plan in its Phase III trials in response to hypersensitivity reactions connected to the glucagon-like peptide-1 analogue (2"The Pink Sheet" DAILY, June 18, 2010). In three studies, patients taking taspoglutide had a significantly greater incidence of nausea and vomiting, as well as injection site skin reactions, compared to those taking comparator drugs. Data presented were from the first 24 weeks of 52-week trials; the full report will be available later in the year, when Roche hopes to have a better handle on the product's safety profile

You may also be interested in...



Roche's Wildcard GLP-1 Not A Spoiler After All; Amylin Stock Soars On Taspoglutide Setback

Roche has voluntarily initiated a risk mitigation strategy to identify patients likely to develop troublesome hypersensitivity reactions and estimates a 12-18 month delay in the development program for the type 2 diabetes therapy.

Outlook 2023: Market Experts On Importance Of Value, Mental Health In A ‘World On Fire’

Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.

Keeping Track: Two Targeted Oncologics And A Novel SGLT-2 Inhibitor Clear US FDA

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS004505

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel